Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Germany Issues Benefit Assessment For InterMune’s Esbriet, Despite Orphan Drug Status

This article was originally published in The Pink Sheet Daily

Executive Summary

Germany’s senior health technology assessment body, the G-BA, has said that InterMune’s Esbriet is beneficial, but says it is unsure to what extent. However, such added value assessments for orphan drugs could be illegal.

You may also be interested in...



U.K.’s NICE Backs Esbriet, Xolair And Orencia After Getting Price Discounts

In a day of three positive recommendations helped by discounts, Bristol’s Orencia for rheumatoid arthritis, Novartis’ Xolair for Asthma and InterMune’s Esbriet for IPF finally make it onto the U.K.’s NHS payroll.

Vertex’s Kalydeco May Face Added Cost Assessments In Germany

Vertex Pharmaceutical’s orphan drug for cystic fibrosis may face an additional reimbursement evaluation in Germany after IQWiG says it may breach the €50 million per year cost threshold.

European HTA Highlights: Discounts Soften NICE Approach But Germany’s IQWiG Shows Its Teeth

It is becoming ever more clear that the overriding factor in NICE’s decision-making process is a desire to see cost-effectiveness, irrespective of the clinical benefit of a drug. But in Germany, companies are challenged by IQWiG’s tightened-up, science-based review system.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143162

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel